Department of Clinical Neuroscience, Headache Unit, C. Besta Neurological Institute and Fundation, Via Celoria 11, 20133 Milan, Italy.
Neurol Sci. 2013 May;34 Suppl 1:S175-7. doi: 10.1007/s10072-013-1376-y.
Patients with chronic migraine (CM) and medication overuse (MO) have high frequency of psychiatric comorbidity. Aims of this open label, prospective, independent study were: to evaluate the efficacy of duloxetine in a sample of patients with MO due to CM and with concomitant depression; to investigate, if the presence of OCD influences the outcome in this subgroup of patients. A total of 50 consecutive patients (40 F,10 M, aged 20-65 years, mean 39.4 years) from those attending our Headache Center to undergo an inpatient withdrawal programme followed by anti-migraine prophylaxis was enrolled. After a 1-month baseline period, all patients were prescribed duloxetine 30 mg in the morning for the first week, and 60 mg for the following 12 weeks. They filled a daily headache diary during the whole study period. They also completed Hamilton depression rating scale (HDRS) and migraine disability assessment scale (MIDAS) at baseline and at the 12-week follow-up. The primary outcome measure was the percentage of responders, i.e. of patients with a reduction ≥50 % in headache frequency as well as in symptomatic drug consumption. Comparison between patients with and without OCD was performed. Our results showed a rather high responder rate in the total sample (64 %), while none of the patients with OCD fell among responders. MIDAS and HDRS scores had a more evident decrease in patients without OSD. These findings suggest that duloxetine may be effective in patients with MO due to CM and with comorbid depression. They also confirm the importance of a systematic assessment of the psychopathological profile in these patients, and indicate that clinicians should be aware of the relevant prognostic role of OCD in favoring a poor outcome and persistent disability in headache patients with MO.
患有慢性偏头痛 (CM) 和药物过度使用 (MO) 的患者常伴有精神共病。本开放性、前瞻性、独立研究的目的是:评估度洛西汀在因 CM 而发生 MO 且伴有抑郁的患者样本中的疗效;探讨强迫症 (OCD) 是否会影响这组患者的预后。共纳入 50 名连续就诊于头痛中心的患者(40 名女性,10 名男性,年龄 20-65 岁,平均 39.4 岁),他们将接受住院戒断方案,然后进行偏头痛预防治疗。在 1 个月的基线期后,所有患者均被处方度洛西汀 30mg,第 1 周每天 1 次,随后 12 周每天 2 次。患者在整个研究期间填写每日头痛日记。他们还在基线和第 12 周随访时填写汉密尔顿抑郁量表 (HDRS) 和偏头痛残疾评估量表 (MIDAS)。主要疗效指标是应答者的比例,即头痛频率以及症状性药物使用减少≥50%的患者比例。比较了伴有和不伴有 OCD 的患者。我们的结果显示,总样本的应答率相当高(64%),而没有 OCD 的患者中没有应答者。在没有强迫症的患者中,MIDAS 和 HDRS 评分下降更为明显。这些发现表明,度洛西汀可能对因 CM 而发生 MO 且伴有共病抑郁的患者有效。它们还证实了在这些患者中系统评估精神病理特征的重要性,并表明临床医生应注意 OCD 的相关预后作用,这有利于 MO 头痛患者的不良预后和持续残疾。